Business Wire

ELLIOTT-ADVISORS-(UK)

19.7.2018 09:32:05 CEST | Business Wire | Press release

Share
Elliott Advisors (UK) Statement on thyssenkrupp AG

Funds advised by Elliott Advisors (UK) Limited (“Elliott”) are significant shareholders in thyssenkrupp AG (“thyssenkrupp” or the “Company”).

Elliott notes recent press coverage referencing the contents of a private letter Elliott sent to the thyssenkrupp Supervisory Board yesterday morning. In order to avoid any misunderstandings or misrepresentations of its substance, Elliott is hereby making the full text of the letter public.

***

The Members of the Supervisory Board

thyssenkrupp AG

thyssenkrupp Allee 1

45143 Essen


18 July 2018

Ladies and Gentlemen,

We note the resignation of Professor Dr. Ulrich Lehner as chairman of the Supervisory Board of thyssenkrupp AG.

When we met with Professor Lehner in Essen on 27th June he and we assured each other of our desire to develop a constructive working relationship. Professor Lehner’s comments in the interview he gave to Die Zeit on 12th July suggest that he did not give those assurances in good faith.

In the course of the interview with Die Zeit Professor Lehner gave his account of the current situation at thyssenkrupp and specifically singled out three shareholders: Krupp-Stiftung, Cevian and Elliott. Against this background, he denounced the behavior of certain ‘activist investors’ as ‘psycho-terror’ and accused them of ‘placing lies in public’, making ‘unjustified requests for resignations’, causing executives to seek ‘psychiatric counselling’ or even going as far as ‘harassing families and neighbours’, concluding that such shareholders are ‘not a benefit’ to the company. Any reasonable reader of this interview would have concluded that he was accusing Elliott of engaging in such behavior. To be clear, any such accusation is categorically untrue and is defamatory. As Professor Lehner could not have had any evidence for such accusations, we assume that he made them maliciously or, at least recklessly.

Our engagement with Professor Lehner and, before him, Dr Hiesinger in respect of thyssenkrupp cannot be described as anything other than the reasonable actions of a responsible, concerned and engaged investor. We have not at any stage, and contrary to Professor Lehner’s comments, demanded a dismantling (‘Zerschlagung’) of thyssenkrupp. Nevertheless, the company should continue to consider any structural evolution, such as the Steel JV, where such changes are determined to be in the interests of all stakeholders. You will be aware that, prior to our meeting with Professor Lehner, we had written to Dr Hiesinger on 24th May indicating our support for the Steel JV while at the same time pointing to analytical indicators that suggested better terms should be achievable in the negotiation. For that reason, we expected the Management Board to have negotiated a better transaction for the benefit of all stakeholders and the final outcome is therefore, from our point of view, very disappointing. The negotiated transaction relinquishes control over one of thyssenkrupp’s key legacy assets, and contributes it to a JV at a value considerably below that which could have been achieved. This view is shared by other investors and stakeholders, and arguably the board, given that the terms of the JV were ultimately amended, albeit insufficiently in our opinion.

We do not know if Professor Lehner’s resignation was required or requested by the Supervisory Board in response to his Die Zeit interview. We would expect that in circumstances where its chairman has made statements that untruthfully disparage shareholders the Supervisory Board would wish to take steps to remedy that situation. We therefore consider that it would be appropriate for the company and the Supervisory Board to distance itself from Professor Lehner’s defamatory remarks by publicly stating that the company does not support them and does not view them as truthful. To the extent the company is in a position to do so, it should take steps to ensure that Professor Lehner publicly withdraws these falsehoods and does not repeat them.

Notwithstanding these recent events, we hope that Professor Lehner’s resignation will now allow Elliott to establish the constructive working relationship with the new chairman and the Supervisory Board that we had hoped to build with him.

In that spirit, we look forward to the appointment of a new Chairman of the Supervisory Board in the short term and we welcome the appointment of Guido Kerkhoff as interim CEO, in that it provides some stability to the group prior to the appointment of a new Chief Executive. However, this interim period must be kept short so that thyssenkrupp may quickly be set on a path to prosperity and growth. Shareholders expect an unbiased search for a new external CEO, driven by what is best for the company and all of its stakeholders, including shareholders.


Yours faithfully,


Elliott Advisors (UK) Limited

About Elliott

Elliott Management Corporation manages two multi-strategy funds which combined have approximately $35 billion of assets under management. Its flagship fund, Elliott Associates, L.P., was founded in 1977, making it one of the oldest funds of its kind under continuous management. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, and employees of the firm. Elliott Advisors (UK) Limited is an affiliate of Elliott Management Corporation.

Contact:

Media Contacts
London
Elliott Advisors (UK) Limited
Sarah Rajani CFA, +44 (0) 20 3009 1475
srajani@elliottadvisors.co.uk
or
Germany
Charles Barker Corporate Communications
Thomas Katzensteiner / Tobias Eberle, +49 69 79 40 90 25 / 24
Thomas.katzensteiner@charlesbarker.de / tobias.eberle@charlesbarker.de

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hologic Signs Definitive Agreement to Acquire Reveal Genomics19.10.2026 21:30:00 CEST | Press release

Acquisition would expand Hologic’s oncology diagnostics portfolio to help inform treatment decisions for more women with breast cancer Hologic, a global leader in women’s health, today announced that it has signed a definitive agreement to acquire Reveal Genomics, a precision oncology company based in Barcelona, Spain, that develops advanced genomic diagnostic tests to help personalized cancer treatment, including its HER2DX test to help optimize therapy for patients with HER2-positive breast cancer. Breast cancer remains one of the most significant health challenges women face today. Reveal Genomics’ tests are highly complementary to Hologic’s existing oncology diagnostics, including the Breast Cancer Index® (BCI) test, the guideline-recognized genomic assay to help inform decisions regarding extended endocrine therapy in women with HR+ early-stage breast cancer. The combination of Hologic’s existing testing with Reveal Genomics’ portfolio represents a significant expansion of Hologic

An Active Role in Freshness: ProAmpac Introduces ProActive Intelligence Shelf Protect19.10.2026 21:27:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, introduces ProActive Intelligence™ Shelf Protect (SP) Series, giving food producers a new way to help preserve product quality and reduce costly spoilage. Designed for select meat, seafood, and dairy applications, the technology is FDA- and USDA-compliant for intended uses in fresh beef, fresh pork, cooked sausage, deli meat, fresh salmon, and fresh cheese. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019305953/en/ Clearshield®-SP Shrink Bag This direct food-contact biotechnology packaging helps reduce microbial growth associated with food spoilage in intended applications, supporting longer shelf life throughout storage and distribution. Shelf Protect’s patented biotechnology is built directly into food-contact packaging film. “For meat processors, every product lost represents an investment in production, packaging, and distribution that goes unreal

Vedanta Ltd Doubles Zinc Capacity in South Africa with US$ 600 Mn investment19.10.2026 19:19:00 CEST | Press release

Vedanta Limited doubled its annual zinc production capacity to 500,000 tonnes1in South Africa through an investment of nearly US$ 600 Mn at Gamsberg (Phase II) at Vedanta Zinc International (VZI). Gamsberg has one of the world’s most significant zinc deposits and is VZI’s flagship zinc mine. Inaugurated by South African President Cyril Ramaphosa and Vedanta Limited Director Priya Agarwal-Hebbar, this expansion marks one of the decade’s largest mining investments in South Africa. It advances Vedanta Limited’s position as the world’s largest2 zinc producer, with a vision of achieving 3 million tonnes of annual production across India and South Africa. Of this, 2 million tonnes are targeted from its subsidiary, Hindustan Zinc Limited the world’s largest integrated zinc producer, while Vedanta Zinc International business aims to contribute 1 million tonnes annually. This expansion strengthens the ZAR 21 Bn (nearly US$ 1.5 Bn) investment commitment Vedanta made at the 2018 South Africa Inve

Unlocking Digital Gold’s US$700bn Opportunity19.10.2026 18:00:00 CEST | Press release

The digital gold market, worth US$45–55bn today, could unlock up to US$700bn in latent demand, according to new research from World Gold Council and Boston Consulting Group. The report points to substantial untapped appetite among retail investors, with nearly nine in ten surveyed saying they would consider digital gold under the right conditions. The US$700bn opportunity represents the report’s estimate of total latent demand that could be released if today’s barriers to adoption were removed, rather than a near-term forecast. The report’s five-year base case sees digital gold growing by around 27% a year to US$160–170bn by 2031. That could rise to US$270–280bn over the same time if more barriers fall faster. Momentum is already building as financial markets undergo a broader digital transformation, bringing tokenised investment products increasingly into the mainstream. Tokenised gold, one segment of the digital gold market alongside vaulted digital gold, has grown fivefold in value

Roquette Brings Broad Portfolio of Excipient Solutions and Technical Expertise to AAPS PharmSci 360 202619.10.2026 16:00:00 CEST | Press release

Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will showcase its expansive portfolio of excipients, capsules, coatings, and biopharma solutions at AAPS PharmSci 360 2026. The conference and trade show will take place October 26-28 in New Orleans, Louisiana, USA. At Booth 1100 in the exhibit hall, Roquette’s Health & Pharma Solutions team will share their expertise across controlled-release technologies, hydroxypropyl beta-cyclodextrins, and sustainable formulation approaches, alongside a comprehensive portfolio of innovative solutions designed to address the evolving needs of pharmaceutical developers. “AAPS PharmSci 360 is a key opportunity to share our latest innovations, as well as highlight the breadth and depth of our scientific know-how that helps our customers solve complex formulation challenges,” said Peter Freed, Head of Technical Service & Development North America for Roquette’s Health & Pharma Solutions Business Unit. “From a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye